Description

GLP-3 / R3T – Pre-filled Laboratory Cartridge for In Vitro Research (10 mg or 20 mg / 3 ml)

Synthetic tri-agonist research peptide of GLP-1, GIP, and glucagon (GCGR) receptors in a pre-formulated stabilized buffered solution for in vitro research on receptor dimerization, intracellular cAMP signaling, lipid metabolic flux, and mitochondrial bioenergetics

Overview & Mechanism of Action (In Vitro)

GLP-3 / R3T is an advanced synthetic acylated peptide engineered for experimental biology and laboratory research into multi-receptor signaling networks. In molecular endocrinology, it serves as a primary reference standard for investigating coordinated triple activation of metabolic pathways in cell culture models:

• Simultaneous Activation of GLP-1R, GIPR, and GCGR: Exhibits balanced binding affinity across the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR), enabling detailed mapping of synergistic receptor complex activation in vitro.
• Modulation of the Adenylate Cyclase and cAMP Cascade: Upon binding to -coupled receptors, it stimulates intracellular cyclic adenosine monophosphate () synthesis and downstream protein kinase A (PKA) activation in experimental cell models.
• Stimulation of Lipid Oxidation & Metabolic Flux In Vitro: Direct activation of glucagon receptors in hepatocyte and adipocyte cell lines triggers enzymatic pathways governing fatty acid -oxidation and thermogenic marker expression (UCP-1).
• Pre-formulated Format for Precise Laboratory Dispensing: The stabilized liquid matrix within a 3 ml cartridge eliminates manual reconstitution variability, ensuring exceptional homogeneity and concentration consistency for micro-dispensing in automated and semi-automated laboratory systems.

Technical & Chemical Specifications

• Classification: Tri-Agonist of GLP-1R / GIPR / GCGR / Research Peptide Solution (RUO)
• Product Format: Pre-filled calibrated laboratory cartridge (3 ml volume)
• Available Strength Variants:
  • 10 mg / 3 ml (approx. 3.33 mg/ml concentration)
  • 20 mg / 3 ml (approx. 6.67 mg/ml concentration)
• Form: Sterile stabilized solution / Ready-to-Use (RTU)
• Solution Matrix: Sterile buffered isotonic solution for laboratory use (pH-optimized, requires no reconstitution or dilution)
• Storage Conditions: Store at 2–8 °C in a dark, refrigerated environment. Do not freeze. Maintain standard laboratory cold-chain protocols to preserve compound stability.

Scientific References & Literature

• Coskun, T., et al. A novel triple GIP, GLP-1, and glucagon receptor agonist: In vitro receptor activation, signaling profiles, and metabolic characterization. Cell Metabolism, 2022.
• Urva, S., et al. In vitro signaling dynamics and downstream transcription patterns of triple incretin receptor agonists. Molecular Metabolism, 2023.
• Jall, S., et al. Synergistic receptor pharmacology: Dissecting the individual contributions of GIP, GLP-1, and glucagon in cellular models. Nature Communications, 2021.
• Finan, B., et al. Multireceptor endocrine pharmacology: Molecular engineering and in vitro profiling of monomeric peptides. Endocrine Reviews, 2020.

Legal Disclaimer & Terms of Purchase

This product is classified and supplied strictly for laboratory, scientific, and in vitro research purposes only (Research Use Only – RUO). The stabilized peptide solution and mechanical cartridge are not drugs, medicines, weight-loss agents, dietary supplements, or cosmetic products, and are not intended for human or veterinary consumption, oral ingestion, direct administration, injection, or diagnostic procedures.

By placing an order, the purchaser explicitly confirms that they are at least 18 years of age, possess the requisite professional qualifications and laboratory infrastructure to safely handle research substances, and are fully conversant with all relevant laboratory safety protocols. The seller assumes no liability for any use contrary to these terms.